Direxion Daily S&P Biotech Bear 3X ETF (LABD) and ProShares UltraShort S&P500 (SDS) represent two leveraged inverse exchange-traded funds (ETFs) designed for investors seeking amplified downside exposure. These products do not compete directly for the same mandate; instead, they offer differentiated strategies—one focused on the volatile biotechnology sector and the other on the broad U.S. equity market. Investors may evaluate them as tactical tools for hedging or expressing bearish views in distinct segments of the market environment.
Direxion Daily S&P Biotech Bear 3X ETF (LABD) seeks daily investment results, before fees and expenses, of 300% of the inverse of the S&P Biotechnology Select Industry Index. The fund is non-diversified and structured as a leveraged inverse product that resets exposure daily through financial instruments including swap agreements and futures contracts. It maintains an expense ratio of 1.07%. Because the strategy targets a single sector, it exhibits concentrated thematic risk tied to biotechnology developments, regulatory changes, and clinical trial outcomes. The fund does not hold a diversified basket of equities but achieves its objective synthetically.
ProShares UltraShort S&P500 (SDS) seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the S&P 500 Index. The ETF employs derivatives to deliver its leveraged inverse exposure and resets daily. It features an expense ratio of 0.91% and provides broad-market downside participation across large-cap U.S. companies. Like other daily-reset leveraged products, SDS is engineered for short-term trading horizons. The fund’s synthetic structure results in minimal direct equity holdings while maintaining high liquidity for tactical positioning.
Biotechnology and broad equity markets operate under different macroeconomic influences. Biotechnology faces sector-specific catalysts including clinical data readouts, Food and Drug Administration (FDA) decisions, patent expirations, and merger and acquisition (M&A) activity. Meanwhile, the S&P 500 reflects overall corporate earnings, interest rate expectations, inflation trends, and geopolitical developments. Both sectors can experience heightened volatility during periods of economic uncertainty or shifts in risk sentiment, creating environments where inverse leveraged products may see increased tactical interest.
In recent market cycles, Direxion Daily S&P Biotech Bear 3X ETF (LABD) has demonstrated amplified sensitivity to biotechnology-specific news flow and sector rotation, often exhibiting greater day-to-day volatility than broad-market products. ProShares UltraShort S&P500 (SDS) has tracked inverse movements in the S&P 500 with a lower leverage multiple, resulting in comparatively moderated daily swings. Relative positioning depends on whether investors prioritize sector-specific downside in healthcare innovation or general market hedging. Both vehicles experience path dependency over multi-day periods, underscoring their role as short-term tactical instruments rather than core holdings.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Visit the AI Screener to explore current opportunities.
Based on structural characteristics, cost efficiency, and diversification profile, Tickeron’s AI would currently assign a probabilistic preference toward ProShares UltraShort S&P500 (SDS) for investors seeking broad-market inverse exposure. The lower expense ratio, wider liquidity profile, and alignment with overall equity market movements provide a more consistent framework for tactical hedging compared with the higher-cost, sector-concentrated approach of Direxion Daily S&P Biotech Bear 3X ETF (LABD).
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
LABD saw its Momentum Indicator move above the 0 level on November 12, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 85 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for LABD just turned positive on November 16, 2026. Looking at past instances where LABD's MACD turned positive, the stock continued to rise in 49 of 52 cases over the following month. The odds of a continued upward trend are 90%.
LABD moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LABD crossed bullishly above the 50-day moving average on November 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +10.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABD advanced for three days, in 246 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
The Aroon Indicator entered an Uptrend today. In 141 of 156 cases where LABD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
LABD broke above its upper Bollinger Band on November 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Moving Average Convergence Divergence (MACD) for SDS turned positive on November 16, 2026. Looking at past instances where SDS's MACD turned positive, the stock continued to rise in 44 of 48 cases over the following month. The odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 16, 2026. You may want to consider a long position or call options on SDS as a result. In 61 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
SDS moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SDS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +11.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where SDS advanced for three days, in 231 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 126 of 137 cases where SDS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
SDS broke above its upper Bollinger Band on November 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
| LABD | SDS | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Declines ODDS (%) | 13 days ago 90% | 13 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |